Perfect Day’s precision fermentation plant at Bharuch, Gujarat is inside its stated commissioning window. The company said in December 2025 that initial operations would begin in the second half of 2026, with a controlled ramp through 2027. That window is open now.
What has never been published, at any point in the twenty months since the foundation stone was laid, is how much the plant can make.
There is no capacity figure in litres or tonnes. There is no capex figure. There is no employment figure. We checked the December 2025 interview, both independent reports of the December 2024 groundbreaking, Zydus Lifesciences’ investor announcement of the joint venture, and Perfect Day’s own newsroom. The only physical number in the public record is that the site spans 27 acres.
For a facility described at groundbreaking as the world’s first precision fermentation-based dairy protein factory of its kind, that is a striking absence — and it is the reason this piece exists. A publication that covers cost per kilogram has to note when the denominators are missing.
The timeline, and the slip inside it
| Date | Event |
|---|---|
| November 2022 | Perfect Day completes acquisition of Sterling Biotech Limited out of insolvency; announces FSSAI approval for its non-animal whey protein |
| 23 August 2024 | Zydus Lifesciences agrees to buy Perfect Day’s ~50% shareholding in SBL; SBL becomes a 50:50 joint venture with equal board representation |
| December 2024 | Foundation stone laid at Bharuch; 27 acres; reported as “operational by the first quarter of 2026” |
| 15 December 2025 | Chief operational officer Marshall Bredwell says initial operations will begin in the second half of 2026, with ramp-up into 2027 |
The two announcements are a year apart and they do not agree. At groundbreaking the plant was reported as operational by Q1 2026. Twelve months later the company itself put initial operations in H2 2026 with a controlled ramp into 2027 — a slip of roughly two to four quarters, disclosed by the company rather than discovered.
We want to be fair about what that means. A two-to-three-quarter slip on a first-of-its-kind industrial plant is unremarkable by the standards of this sector; several of the projects in our fermentation capacity map have moved further. It is worth recording precisely because it is ordinary, and because the original date is the one that will otherwise be remembered.
The practical consequence: if you are modelling supply of recombinant beta-lactoglobulin for 2027 contracts, use the H2 2026 start and the “controlled ramp-up” language, not the Q1 2026 date still circulating in the 2024 coverage. And note that ramp-up is not nameplate.
Approval came first, and the market never did
The interesting thing about India here is not that Perfect Day cannot sell there. It is that it has been able to for nearly four years and evidently has not.
FSSAI granted the company prior approval for its non-animal whey protein under India’s Approval of Non-Specified Food and Food Ingredients Regulations, announced in Perfect Day’s own release of 30 November 2022 — the same release that announced the Sterling Biotech acquisition. The strategy stated in that release is unambiguous: the company would export animal-free protein produced in India to meet increasing global customer demands while it works on building a roadmap for domestic commercial opportunities.
That roadmap has not produced a visible Indian market. We found no source stating the product is on sale in India today, and the 2022 export-first language remains the last word we could locate.
Set that against the regulatory position elsewhere:
| Jurisdiction | Status | Instrument | Date |
|---|---|---|---|
| India | Approved | Non-Specified Food and Food Ingredients Regulations | Announced 30 November 2022 |
| United States | Cleared, “no questions” | GRAS Notice GRN 863, beta-lactoglobulin from Trichoderma reesei | Notice 29 March 2019; closure 25 March 2020 |
| European Union | Not approved, dossier not validated | Regulation (EU) 2015/2283 | Submitted 2022; still unassessed as of April 2024 |
The EU line is the one that has not moved. An EFSA spokesperson, asked about the application, said: “If information is missing or the application fails to meet any of the requirements, we go back to the applicant… That is what happened in this case.” Perfect Day did not respond to that publication’s request for comment. This is the same pattern documented in our analysis of Europe’s precision fermentation approval gap: applications that never reach assessment, rather than applications that fail it.
The US clearance is worth reading closely rather than treating as a general permission. GRN 863 covers beta-lactoglobulin produced by Trichoderma reesei, notified by Perfect Day, Inc. of Berkeley, California, on the basis of scientific procedures. It excludes infant formula and USDA-regulated products. That is a narrower grant than “approved in the US” suggests, and it shapes which finished categories the Bharuch output can actually enter — a point we made at length about route to market for precision-fermented casein.
The practical consequence: geography of manufacture and geography of permission are now separable. A buyer sourcing from Bharuch is buying Indian-made protein into a US clearance and an unresolved EU file. Confirm the destination market’s status against the specific molecule and organism named in the notice, not against the company.
What the joint venture actually is
Zydus Lifesciences announced on 23 August 2024 that a wholly owned subsidiary had signed an agreement for Perfect Day to sell its approximately 50% shareholding in Sterling Biotech Limited, making SBL a 50:50 joint venture with equal board representation. The consideration was reported at ₹550 crore, around $66 million.
SBL is not a greenfield alt-protein company. Zydus’s own filing describes it as making fermentation-based API products and gelatine, operating two manufacturing facilities in Gujarat. Perfect Day had bought it out of bankruptcy for a reported $78 million in 2022 — so the reported 2024 transaction values half the business at close to what the whole of it cost two years earlier. Green Queen, citing Business Standard, described the purchase as at a 70% premium and noted that Zydus shares fell 5.9% on the following Monday. Nomura put SBL’s 2023 revenue at ₹450 crore, about $53.6 million, with annual sales up 10% since 2021.
Zydus brings scale that Perfect Day does not have: 27,000 employees worldwide and 1,400 R&D scientists, per its own release.
This is the structural point. Perfect Day did not build fermentation capacity in India; it bought a distressed pharmaceutical fermentation business with existing fermenters, said the acquisition would “double the company’s production capability in the near-term” with the addition of four high-value assets, then sold half of it to a domestic pharmaceutical major and is building the new plant as a joint venture. The route to tanks ran through pharma insolvency, not through a food-sector capital raise.
An unnamed source close to the company told AgFunderNews that the plant in India took two and a half years and in the US it would be four to five. That is the clearest statement of the Indian advantage anyone has put on the record — and note that it is about schedule, not cost.
The scale claims have a history
Perfect Day’s stated ambitions have been large for some time, and checking them against the present is instructive rather than merely unkind.
In December 2022, co-founder Ryan Pandya said the company would have capacity for “thousands of metric tons” of beta-lactoglobulin through four commercial-scale facilities on three continents, with a long-term ambition of “tens of thousands of metric tons of our protein over the next five years” and production having scaled over 500% over the past year.
Four years into that five-year window, the company is commissioning a plant whose capacity it does not disclose, having in the interim laid off 15% of its workforce, 134 employees, in July 2023, exited its consumer business, sold its D2C subsidiary The Urgent Company to Superlatus on a $3.15 million promissory note in September 2023, and seen both founders depart around a $90 million raise in January 2024.
The December 2025 position is more contained and, read plainly, more credible. Bredwell said the current plant is “effectively sold out” — that letters of intent have been converted into signed commercial contracts — and that remaining LOIs are “primarily focused on plant 2 capacity planning.” The product focus has narrowed to beta-lactoglobulin only, with lactoferrin and casein explicitly deprioritised. The company is described as “confident in instant profitability at plant launch.”
Narrowing to one molecule and selling out capacity before commissioning is what a company does when it has stopped optimising for optionality. Whether it is enough is a different question: the same report carries an unnamed source saying “I think they’ll have to raise again next year.” Board co-chairs are named as Aftab Mathur of Temasek and Patrick Zhang of Horizons Ventures, described as deeply involved, and no chief executive has been announced since Narayan TM’s departure.
The practical consequence: “effectively sold out” is a commercial claim about an undisclosed denominator. It tells a prospective buyer that plant 1 is unavailable and that plant 2 is where the conversation goes — which is useful — but it cannot be used to infer volume.
India is becoming a fermentation base regardless
The Perfect Day story is easy to read as a single company’s manoeuvring. The wider signal is that India is accumulating food-capable fermentation capacity from several directions at once, and unlike Bharuch, some of it publishes numbers.
| Operator | Location | Disclosed capacity | Status |
|---|---|---|---|
| Laurus Bio | Bangalore | 250 KL installed; R3 adding up to 500 KL with full downstream | R3 operational Q3 2026; stated vision of 2 million litres across phases |
| StrainX Bioworks | Bhopal | 10,000 L installed, demonstrated at that scale | Modular design targeting 100,000 L over 12–18 months from May 2026 |
| Glatt and PreferCo | Genome Valley, Hyderabad | Scale-up support to 1,500 L bioreactor | Launched at BioAsia 2026, February 2026 |
StrainX exited stealth on 25 May 2026 with $13 million led by Prime Venture Partners and Leo Capital, and its position is the mirror image of Perfect Day’s: it holds self-affirmed GRAS for one molecule with FDA notified, while awaiting regulatory approval for multiple ingredients in India. Chief executive Akshay Mittal’s assessment of the domestic gap is worth quoting because it is specific: “In India, there are still limited precision fermentation manufacturing options optimised for food applications, especially outside pharma-oriented infrastructure.”
That is precisely the constraint Perfect Day solved by buying a pharmaceutical fermentation business.
Rajiv Bhide of Glatt Systems, speaking at the Hyderabad launch, put India’s bioeconomy at $10 billion in 2014, $166 billion in 2024, and a target of $300 billion by 2030. Those are headline national figures rather than fermentation-specific ones, and should be read as direction rather than measurement.
The counter-argument
Not disclosing capacity is defensible, and the case deserves stating properly.
Capacity is competitively sensitive in a market where a handful of buyers negotiate against a handful of suppliers. Publishing nameplate volume tells every counterparty exactly how much leverage they have and tells competitors what to underbid. If the plant is genuinely sold out, the commercial benefit of publishing is close to zero and the cost is real. Zydus is a listed company with its own disclosure obligations and its own reasons for caution about a JV’s forward volumes.
There is also a fair reading in which the absent capex figure is simply a JV artefact: investment split across two partners, one of them listed, with the API business and the new protein plant sharing a site history that makes clean attribution hard.
Both points hold. Neither changes the position of a reader trying to plan. The observation stands not as an accusation but as a limit: claims like “world’s first,” “substantially booked” and “effectively sold out” are not verifiable without a denominator, and should be treated as directional statements rather than as data — the same conclusion we reached about modelled fermentation costs.
What we could not establish
- Fermentation capacity at Bharuch, in litres or tonnes. Absent from the AgFunderNews interview, both groundbreaking reports, the Zydus investor release and Perfect Day’s newsroom.
- Capex for the Bharuch plant. The only figure we encountered came from an aggregated company-profile page with no original reporting behind it, and we have not published it.
- Employment at the site. No figure anywhere.
- Whether Perfect Day protein is on sale in India today. No source states that it is. We are reporting the absence of evidence, not evidence of absence.
- The FSSAI approval reference number. FSSAI’s product approval list PDF returned no extractable text on retrieval; a status-of-applications file could not be retrieved. The approval itself is confirmed by the company’s release and by GFI India’s regulatory tracker.
- Perfect Day’s Singapore status. Its products are sold in Singapore, but the company does not appear among the fermentation entries on SFA’s published list of approved novel foods. It is possible the ingredient is not classed as a novel food there. We are not asserting either way.
- Canadian and Israeli status. Nothing found.
- How many facilities SBL actually comprises. Zydus’s filing says two in Gujarat; Perfect Day’s 2022 release refers to four high-value assets; other accounts describe a Tamil Nadu site that may have closed. These are not reconcilable from public sources.
- Total funds raised. AgFunderNews reported more than $825 million in December 2025; coverage of the January 2024 round put the total at $840 million. We could not reconcile the two and have not used either as a settled figure.
- The quantum of the Olon lawsuit filed in April 2024 — reported both as $112m in unpaid bills plus $32m in damages, and as a $134m suit. It was voluntarily dismissed in January 2025 with each party bearing its own costs, and Olon subsequently became an investor.
- Any numeric India-versus-US or India-versus-EU capex or opex comparison. We found no disclosed figures on a source we were able to fetch. The only on-the-record advantage claim we could verify concerns schedule — two and a half years versus four to five — not money.
What to watch
Does initial operation actually occur before 31 December 2026? This is the stated commitment and the year is more than half gone. A slip past year-end would make the total movement from the original Q1 2026 date a full year or more.
Does a capacity figure ever appear? The most likely place is a Zydus disclosure to the Indian exchanges rather than a Perfect Day announcement, since a listed JV partner has obligations a private company does not.
Does Perfect Day raise again in 2026 or 2027, and does a chief executive get named? Both were flagged in December 2025 and neither has visibly resolved.
Does India become a market rather than only a plant? Four years of approval without evident domestic sale is the anomaly in this story. If Bharuch commissions and the output still ships out, the pattern we described in where to launch a precision-fermented protein needs a new column: jurisdictions that will let you make it, distinct from jurisdictions that will buy it.